Transfusion Medicine Reviews
Volume 11, Issue 3 , Pages 155-172 , July 1997

The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection

  • Steven Kleinman

      Affiliations

    • Retrovirus Epidemiology Donor Study, Rockville, MD USA
    • Westat Inc, Rockville, MD USA
    • Irwin Memorial Blood Centers, San Francisco, CA USA
    • University of California at San Francisco, San Francisco, CA USA
    • American Red Cross Greater Chesapeake and Potomoc Region, Baltimore, MD USA
    • American Red Cross Southeastern Michigan Region, Detroit, MI USA
    • American Red Cross Southern California Region, Los Angeles, CA USA
    • Oklahoma Blood Institute, Oklahoma City, OK USA
    • National Heart, Lung, and Blood Institute, Bethesda, MD USA
    • Corresponding Author InformationAddress reprint requests to Steven Kleinman, MD, 1281 Rockcrest Ave, Victoria, British Columbia, V9A 4W4, Canada.
    • ,
  • Michael P. Busch

      Affiliations

    • Retrovirus Epidemiology Donor Study, Rockville, MD USA
    • Westat Inc, Rockville, MD USA
    • Irwin Memorial Blood Centers, San Francisco, CA USA
    • University of California at San Francisco, San Francisco, CA USA
    • American Red Cross Greater Chesapeake and Potomoc Region, Baltimore, MD USA
    • American Red Cross Southeastern Michigan Region, Detroit, MI USA
    • American Red Cross Southern California Region, Los Angeles, CA USA
    • Oklahoma Blood Institute, Oklahoma City, OK USA
    • National Heart, Lung, and Blood Institute, Bethesda, MD USA
    • ,
  • James J. Korelitz

      Affiliations

    • Retrovirus Epidemiology Donor Study, Rockville, MD USA
    • Westat Inc, Rockville, MD USA
    • Irwin Memorial Blood Centers, San Francisco, CA USA
    • University of California at San Francisco, San Francisco, CA USA
    • American Red Cross Greater Chesapeake and Potomoc Region, Baltimore, MD USA
    • American Red Cross Southeastern Michigan Region, Detroit, MI USA
    • American Red Cross Southern California Region, Los Angeles, CA USA
    • Oklahoma Blood Institute, Oklahoma City, OK USA
    • National Heart, Lung, and Blood Institute, Bethesda, MD USA
    • ,
  • George B. Schreiber

      Affiliations

    • Retrovirus Epidemiology Donor Study, Rockville, MD USA
    • Westat Inc, Rockville, MD USA
    • Irwin Memorial Blood Centers, San Francisco, CA USA
    • University of California at San Francisco, San Francisco, CA USA
    • American Red Cross Greater Chesapeake and Potomoc Region, Baltimore, MD USA
    • American Red Cross Southeastern Michigan Region, Detroit, MI USA
    • American Red Cross Southern California Region, Los Angeles, CA USA
    • Oklahoma Blood Institute, Oklahoma City, OK USA
    • National Heart, Lung, and Blood Institute, Bethesda, MD USA

References 

  1. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following primary HIV infection: Implications for management of exposed health care workers. Am J Med. 1997;102:51–58
  2. Manns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer. 1992;35:91–97
  3. (editorial) Busch MP, Alter HJ. Will human immunodeficiency virus p24 antigen screening increase the safety of the blood supply and, if so, at what cost?. Transfusion. 1995;35:536–539
  4. Cummings PD, Wallace EL, Schorr JB, et al. Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody negative. N Engl J Med. 1989;321:941–946
  5. Murphy EL, Bryzman S, Williams AE, et al. Demographic determinants of Hepatitis C virus seroprevalence among blood donors. JAMA. 1996;275:995–1000
  6. Busch MP, Eble BE, Khayam-Bashi H, et al. Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. N Engl J Med. 1991;325:1–5
  7. (letter) Vyas GN, Rawal BP, Busch MP. The risk of HIV transmission by screened blood. N Engl J Med. 1996;334:992
  8. Ward JW, Holmberg SD, Allen JR, et al. Transmission of human immunodeficiency virus by blood transfusions screened as negative for HIV antibody. N Engl J Med. 1988;318:473–478
  9. Kleinman S, Secord K. Risk of human immunodeficiency virus transmission by anti-HIV negative blood. Transfusion. 1988;28:499–501
  10. Selik RM, Ward JW, Buehler JW. Trends in transfusion-associated acquired immunodeficiency syndrome in the United States, 1982 through 1991. Transfusion. 1993;33:890–893
  11. Imagawa DT, Lee MH, Wolinsky SM, et al. Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med. 1989;320:1458–1462
  12. Imagawa D, Detels R. HIV-1 in seronegative homosexual men. N Engl J Med. 1991;325:1250–1251
  13. Jackson JB. Human immunodeficiency virus indeterminate western blots and latent HIV infection. Transfusion. 1992;32:497–499
  14. Lifson AR, Stanley M, Pane J, et al. Detection of human immunodeficiency virus DNA using the polymerase chain reaction in a well-characterized group of homosexual and bisexual men. J Infect Dis. 1990;161:436–439
  15. Farzadagen H, Polis MA, Wolinsky SM, et al. Loss of human immunodeficiency virus type 1 antibodies with evidence of viral infection in asymptomatic homosexual men: A report from the Multicenter AIDS Cohort Study. Ann Intern Med. 1988;108:785–790
  16. Roy MJ, Damalo JJ, Burke DS. Absence of true seroreversion of HIV-1 antibody in seroreactive individuals. JAMA. 1993;269:2786–2789
  17. Rockville, MD Center for Biologics Evaluation and Research, FDA . Revised recommendations for the prevention of human immunodeficiency virus (HIV) transmission by blood and blood products. April 23, 1992;
  18. Centers for Disease Control and Prevention . Persistent lack of detectable HIV-1 antibody in a person with HIV infection—Utah, 1995. Morb Mortal Wkly Rep. 1996;45:181–185
  19. Soriano V, Dronda F, Gonzales-Lopez A, et al. HIV-1 causing AIDS and death in a seronegative individual. Vox Sang. 1994;67:410–411
  20. Korber BTM, MacInnes K, Smith RF, et al. Mutational trends in V3 loop protein sequences observed in different genetic lineage of human immunodeficiency virus type 1. J Virol. 1994;68:6730–6744
  21. Nkengasong JN, Janssens W, Heyndricks L, et al. Genotypic subtypes of HIV-1 in Cameroon. AIDS. 1994;8:1405–1412
  22. Sabino EC, Shpaer EG, Morgado MG, et al. Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. J Virol. 1994;68:6340–6346
  23. O'Brien TR, George JR, Holmberg SD. Human immunodeficiency virus type 2 infection in the United States: Epidemiology, diagnosis, and public health implications. JAMA. 1992;267:2775–2779
  24. Loussert-Ajaka I, Ly TD, Chaix M, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet. 1994;343:1393–1394
  25. Centers for Disease Control and Prevention . Update: HIV-2 infection among blood and plasma donors—United States, June 1992 to June 1995. Morb Mortal Wkly Rep. 1995;42:603–606
  26. Centers for Disease Control and Prevention . Identification of HIV-1 Group O infection—Los Angeles County, California, 1996. Morb Mortal Wkly Rep. 1996;45:561–564
  27. Petersen LR, Satten GA, Dodd R, et al. HIV Seroconversion Study Group Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion. 1994;34:283–289
  28. Busch MP, Lee LLL, Satten GA, et al. Time course of detection of viral and serological markers preceding HIV-1 seroconversion; implications for blood and tissue donor screening. Transfusion. 1995;35:91–97
  29. (abstr 38) Busch MP, Herman SA, Henrard DR, et al. Time course and kinetics of HIV viremia during primary infection. In: Third Conference on Retroviruses and Opportunistic Infections. Washington, DC. Jan 1996;p. 60
  30. 42S Lackritz EM, Kennedy MB, Doll LS, et al. Risk behaviors and test seeking among HIV-1 positive blood donors. (abstr, suppl) Transfusion. 1995;35:
  31. 29S Kleinman S, Secord K, Doyle M. Demographic profile and motivation for donation in donors who have seroconverted for HIV. (abstr, suppl) Transfusion. 1988;28:
  32. Zuck TF. Silent sequences and the safety of blood transfusions. Ann Intern Med. 1988;108:895–897
  33. Busch MP. HIV and blood transfusions: Focus on seroconversion. Vox Sang. 1994;67(suppl 3):13–18
  34. Korelitz JJ, Busch MP, Kleinman SH, et al. Relationship between antibody to hepatitis B core antigen and retroviral infections in blood from volunteer donors. Transfusion. 1996;36:232–237
  35. Korelitz JJ, Williams AE, Busch MP, et al. Demographic characteristics and prevalence of serologic markers among donors who use the confidential unit exclusion process: The retrovirus epidemiology donor study. Transfusion. 1994;34:870–876
  36. AuBuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded HIV test protocols for donated blood. Transfusion. 1997;37:45–51
  37. 41S Busch MP, Satten GA, Herman SA, et al. Time course and kinetics of HIV viremia during primary infection. (suppl, abstr) Transfusion. 1996;37:
  38. 38S Stramer SL, Salemi BL, Sievert WS, et al. Evaluation of US blood donations testing positive for HIV-1 p24 antigen. (Suppl, abstr) Transfusion. 1996;37:
  39. (letter) Kinloch S, Perrin L, Hirschel B. The risk of HIV transmission by screened blood. N Engl J Med. 1996;334:992
  40. Kleinman S, Alter H, Busch M, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multipleantigen HCV enzyme immunoassay. Transfusion. 1992;32:805–813
  41. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis—An analysis with first- and second-generation assays. N Engl J Med. 1991;325:1325–1329
  42. Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327:369–373
  43. (letter) Nelson KE, Donahue JG, Stambolis V. Post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327:1601–1602
  44. Esteban JI, Gonzales A, Hernandez JM, et al. Open prospective efficacy trial of anti-HCV screening of blood donors to prevent post-transfusion hepatitis. In: Holling FB, Lemon SM, Margolis HS editor. Viral Hepatitis and Liver Disease. Baltimore, MD: Williams and Wilkens; 1991;p. 441
  45. 36S Cyrus S, Swenson S, Dembowski J. Removal of HCV infected donors with use of second generation anti-HCV EIA. (abstr, suppl) Transfusion. 1992;32:
  46. Simmonds P, Holmes EC, Cha TA, et al. Classification of Hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993;74:2391–2399
  47. 59S Busch MP, Watanabe K, Smith JW, et al. False negative testing errors in routine viral screening. (abstr, suppl) Transfusion. 1996;37:
  48. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med. 1992;327:1899–1905
  49. Sugitani M, Shindo M, Inchauspe G, et al. Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet. 1992;339:1018–1019
  50. (letter) Kleinman S, Busch J, Holland P. Post-transfusion hepatitis C virus infection. New Engl J Med. 1992;327:1601
  51. Barrera JM, Francis B, Ercilla G, et al. Improved detection of anti-HCV In post-transfusion hepatitis by a third generation ELISA. Vox Sang. 1995;68:15–18
  52. Busch MP, Korelitz JJ, Kleinman SH, et al. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. Transfusion. 1995;35:903–910
  53. Lelie PN, Cuypers HTM, Reesnick HW, et al. Patterns of serological markers in transfusion-transmitted hepatitis C infection using second generation HCV assays. J Med Virol. 1992;37:203–209
  54. 51S Busch MP, Lee SR. Yield of HCV EIA 3.0 vs 2.0 for detection of seroconverting donors. (abstr, suppl) Transfusion. 1996;37:
  55. Alter HJ. To C or not to C: These are the questions. Blood. 1995;85:1681–1695
  56. Blajchman MA, Bull SB, Feinman SV. Post-transfusion hepatitis: Impact of non-A, non-B surrogate tests. Lancet. 1995;345:21–25
  57. Mosley JW, Huang W, Stram DO. Donor levels of serum alanine aminotransferase activity and antibody to hepatitis B core antigen associated with recipient hepatitis C and non-B, non-C outcomes. Transfusion. 1996;36:776–781
  58. Esteban JI, Camps J, Genesca J, et al. Hepatitis C and B: New development. In: Nance SJ editors. Blood Safety: Current Challenges. Bethesda, MD: American Association of Blood Banks; 1992;p. 45–96
  59. Bethesda, MD National Institutes of Health . Infectious disease testing for blood transfusions. NIH Consensus Statement Jan 9–11. 1995;13:1–27
  60. Farci P, London WT, Wong DC, et al. The natural history of infection with hepatitis C virus in chimpanzees: Comparison of serologic responses measured with first and second generation assays and relationship to viremia. J Infect Dis. 1992;165:1006–1011

PII: S0887-7963(97)80037-5

doi: 10.1053/tmrv.1997.0110155

Transfusion Medicine Reviews
Volume 11, Issue 3 , Pages 155-172 , July 1997

Article Tools